Following the September 2024 global withdrawal of Oxbryta (voxelotor) due to safety concerns, several lawsuits have been filed against its manufacturers, Pfizer and Global Blood Therapeutics (GBT). These legal actions allege that the companies failed to adequately warn patients and healthcare providers about the drug’s potential risks, including severe complications such as vaso-occlusive crises (VOCs), organ damage, and fatalities.

One notable case involves plaintiff Tirrell Allen, who began using Oxbryta in August 2024. After starting the medication, Allen reportedly experienced an increased frequency of VOCs, leading to severe pain and health complications. The lawsuit, filed in California, accuses the manufacturers of negligence and failure to provide adequate warnings about the drug’s risks

Patients who have experienced adverse effects from Oxbryta are advised to consult with legal professionals to explore their options for seeking compensation. Law firms specializing in pharmaceutical litigation are currently investigating potential claims related to Oxbryta’s alleged side effects and the circumstances surrounding its recall.